Report Says Indian, Other Drug Makers Face Big Marketing Change
This article was originally published in PharmAsia News
A consultant's report says India's drug makers are bringing about a change in the way they market drugs that will make the marketing model look vastly different in 10 years. Instead of a sales and marketing workforce serving a mass market, PricewaterhouseCoopers said in a report, the Indian industry and others will morph into ones that target specific segments of the market. As a result, the industry's sales forces can be expected to be much smaller and feature new skills based on emphases on different educational training. The report said the focus will be on managing health outcomes rather than selling products. (Click here for more
You may also be interested in...
The US FDA issued only one device-related close-out letter in October.
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.